Bluejay Diagnostics (BJDX)
NASDAQ:BJDX
BJDX Stock Chart & Stats
$0.65
-$0.20(-5.19%)
At close: 4:00 PM EST
$0.65
-$0.20(-5.19%)
Day’s Range― - ―
52-Week Range$1.70 - $40.80
Previous CloseN/A
Volume34.54K
Average Volume (3M)5.27M
Market Cap
$1.89M
Enterprise Value-$4.16M
Total Cash (Recent Filing)$5.16M
Total Debt (Recent Filing)$129.56K
Price to Earnings (P/E)―
Beta0.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding972,215
10 Day Avg. Volume15,571,172
30 Day Avg. Volume5,266,425
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.19
Enterprise Value/Market Cap-2.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.88
Enterprise Value/Ebitda0.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Antibody Production CapacityOwning commercial-scale IL-6 antibody production and inventory for ~9M cartridges materially reduces supply risk and short-term COGS volatility. This durable operational capability supports scalable manufacturing and faster ramp if/when regulatory clearance and commercial demand materialize.
SYMON II Enrollment & Manufacturing ReadinessStrong SYMON II enrollment plus cartridge characterization and robust antibody supply reduce clinical and execution risk. A large, diverse dataset and manufacturing readiness improve the odds of a defensible 510(k) submission and shorten time from clearance to commercialization.
Capital Structure ClarityEliminating prefunded warrants and disclosing remaining cash-exercisable warrants brings clarity to share count and potential future inflows. A clearer cap table reduces investor uncertainty and allows management to plan financing and commercialization more strategically over months.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow forces recurring financing needs, which can dilute shareholders and divert management attention. Until revenue scales, ongoing cash burn constrains investments in commercialization, hiring, and regulatory support, raising execution risk.
Minimal Revenue TractionLack of meaningful revenue demonstrates the business model is unproven commercially. Even with regulatory progress, converting approvals to sustainable sales requires new capabilities; absent revenue, the firm remains dependent on capital markets and partner arrangements.
Very Small Operating ScaleA tiny headcount limits internal capacity for regulatory filings, quality systems, commercial launch, and scaling manufacturing. This increases reliance on external partners, slows execution, and heightens operational risk during the critical transition from development to commercialization.
Bluejay Diagnostics News
BJDX FAQ
What was Bluejay Diagnostics’s price range in the past 12 months?
Bluejay Diagnostics lowest stock price was $1.70 and its highest was $40.80 in the past 12 months.
What is Bluejay Diagnostics’s market cap?
Bluejay Diagnostics’s market cap is $1.89M.
When is Bluejay Diagnostics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bluejay Diagnostics’s earnings last quarter?
Currently, no data Available
Is Bluejay Diagnostics overvalued?
According to Wall Street analysts Bluejay Diagnostics’s price is currently Overvalued.
Does Bluejay Diagnostics pay dividends?
Bluejay Diagnostics does not currently pay dividends.
What is Bluejay Diagnostics’s EPS estimate?
Bluejay Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bluejay Diagnostics have?
Bluejay Diagnostics has 972,215 shares outstanding.
What happened to Bluejay Diagnostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bluejay Diagnostics?
Currently, no hedge funds are holding shares in BJDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bluejay Diagnostics
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Technical Analysis
Aethlon Medical
―
Venus Concept
―
Bone Biologics
―
Tivic Health Systems
―
DIH Holdings US, Inc Class A
―
Ownership Overview
―
Insiders
0.59% Mutual Funds
<0.01% Other Institutional Investors
99.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---